<DOC>
	<DOCNO>NCT00314938</DOCNO>
	<brief_summary>This first clinical study development PHA-794428 pediatric population . Since difference PK and/or PD response may occur adult pediatric subject , deem appropriate first conduct exploratory single dose study pediatric patient assess safety tolerability patient population . In addition add pediatric data facilitate prediction optimal therapeutic dose test repeat dose phase 2b trial child , use PK/PD modeling</brief_summary>
	<brief_title>A Single Dose Study Evaluate PK-PD Response Safety PHA-794428 Children With Growth Hormone Deficiency</brief_title>
	<detailed_description>The study terminate 10-Dec-2007 . Pfizer 's decision terminate program due case injection-site lipoatrophy report clinical Phase 2 study single injection PHA 794428 .</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>1.Male female child minimum age 6 year 2 . Prepubertal define Tanner stag 3 . Growth hormone deficiency 1 . PGHD patient uncontrolled pituitary tumor growth 2 . Tumors within 3 mm optic chiasm 3 . Serum ALT and/or AST &gt; = 1.5 time upper limit normal range</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>